Ladiratuzumab vedotin is a Monoclonal Antibody Conjugated owned by Seagen, and is involved in 4 clinical trials, which are ongoing.

Ladiratuzumab vedotin (SGN-LIV1A) is an antibody-drug conjugate that targets LIV-1 (a zinc transporter), which is expressed in most subtypes of metastatic breast cancer. Zinc is essential for normal cell growth and is tightly controlled in cells by two families of zinc transporters. The aberrant expression of zinc transporters from the LIV-1 family of ZIP (Zrt/Irt-like protein) transporters is implicated in breast cancer. Upon internalization by LIV-1-positive tumor cells, anti-LIV-1 antibody-drug conjugate SGN-LIV1A undergoes enzymatic cleavage to release MMAE into the cytosol. MMAE binds to and inhibits tubulin polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in LIV-1-expressing tumor cells.

The revenue for Ladiratuzumab vedotin is expected to reach a total of $2.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ladiratuzumab vedotin NPV Report.

Ladiratuzumab vedotin is originated and owned by Seagen. Merck & Co is the other company associated in development or marketing of Ladiratuzumab vedotin.

Ladiratuzumab vedotin Overview

Ladiratuzumab vedotin (SGN-LIV1A) is under development for the treatment of HR positive metastatic breast cancer, HER2 positive and negative metastatic breast cancer, LIV-1-positive metastatic triple negative breast cancer, small-cell lung cancer, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, head and neck cancer squamous cell carcinoma, esophageal squamous cell carcinoma gastric cancer, adenocarcinoma of the gastroesophageal junction, metastatic castration-resistant prostate cancer and malignant melanoma. It is administered through the intravenous route. The drug candidate is an antibody-drug conjugate which is comprised of an anti-LIV-1 monoclonal antibody linked to a synthetic cell-killing agent called monomethyl auristatin E (MMAE). The drug candidate is developed based on antibody-drug conjugate (ADC) technology. It was also under development for the treatment of cervical cancer.

Seagen Overview

Seagen, formerly Seattle Genetics, is a biotechnology company that discovers, develops, and markets monoclonal antibody-based therapies for the treatment of cancer. It markets antibody-drug conjugates (ADCs), including Adcetris (brentuximab vedotin), for the treatment of Hodgkin’s lymphoma, T-cell lymphomas and CD30-expressing lymphomas; Padcevtm (enfortumab vedotin-ejfv) for metastatic urothelial cancers; Tukysa (tucatinib) for the treatment of metastatic HER2-positive breast cancers, and Tivdak (tisotumab vedotin-tftv) for the treatment of certain metastatic cervical cancers. The company’s pipeline consists of novel therapies for addressing the unmet medical needs of blood-related cancers and solid tumors. Seagen products and pipeline are based on ADC technology, which targets monoclonal antibodies and delivers agents for killing cancer cells. The company sells its products through specialty distributors. Seagen is headquartered in Bothell, Washington, the US.

The company reported revenues of (US Dollars) US$1,574.4 million for the fiscal year ended December 2021 (FY2021), a decrease of 27.6% over FY2020. The operating loss of the company was US$682.1 million in FY2021, compared to an operating profit of US$596.9 million in FY2020. The net loss of the company was US$674.5 million in FY2021, compared to a net profit of US$613.7 million in FY2020. The company reported revenues of US$510.3 million for the third quarter ended September 2022, an increase of 2.6% over the previous quarter.

Quick View – Ladiratuzumab vedotin

Report Segments
  • Innovator
Drug Name
  • Ladiratuzumab vedotin
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.